EGK alleviates T2DM combined with NAFLD by reducing lipid accumulation through the inhibition of oxidative stress, inflammatory responses, and the SREBP-1c signaling pathway. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.